Marizyme Stock Price To Earnings To Growth
| MRZM Stock | USD 0.05 0.05 1,150% |
Marizyme fundamentals help investors to digest information that contributes to Marizyme's financial success or failures. It also enables traders to predict the movement of Marizyme OTC Stock. The fundamental analysis module provides a way to measure Marizyme's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Marizyme otc stock.
Marizyme |
Marizyme OTC Stock Price To Earnings To Growth Analysis
Marizyme's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Marizyme has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Software sector and 100.0% lower than that of the Information Technology industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
Marizyme Fundamentals
| Return On Equity | -0.5 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (180.85) % | |||
| Current Valuation | 17.35 M | |||
| Shares Outstanding | 10.13 M | |||
| Shares Owned By Insiders | 2.04 % | |||
| Price To Book | 0.37 X | |||
| Price To Sales | 133.06 X | |||
| Revenue | 210.28 K | |||
| Gross Profit | 129.93 K | |||
| EBITDA | (10.83 M) | |||
| Net Income | (11 M) | |||
| Cash And Equivalents | 2.04 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 495.32 K | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 1.74 X | |||
| Book Value Per Share | 1.00 X | |||
| Cash Flow From Operations | (5.79 M) | |||
| Earnings Per Share | (0.39) X | |||
| Number Of Employees | 11 | |||
| Beta | 0.36 | |||
| Market Capitalization | 5.07 M | |||
| Total Asset | 66 M | |||
| Z Score | 6.0 | |||
| Net Asset | 66 M |
About Marizyme Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marizyme's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marizyme using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marizyme based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Marizyme OTC Stock
Marizyme financial ratios help investors to determine whether Marizyme OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.